obesity drug news today glp-1 2025 oct 27 Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine A New Medicare Option for
Description
Emerging research on GLP-1 medications covers fatty liver, kidney disease, sleep apnoea, PCOS, and neurodegeneration
CTLs heterogeneity and plasticity: implications for cancer immunotherapy
These milestones highlight the growing regulatory and clinical momentum supporting expanded uses Ongoing trials are also exploring the impact of GLP-1 agonists on cardiovascular outcomes, liver health, and even neurodegenerative diseases, reinforcing their value in treating systemic metabolic disorders
The reduction appears to be primarily due to decreases among individuals with the highest baseline scores
What are the legal risks of DIY GLP-1 injections
Time-to-onset analysis of amiodarone-associated thyroid dysfunction
